01—Abstract
Summary
Summary of the 10-K filed March 1, 2018. Cited figures are marked; the original filing is the authoritative source.
Tempur Sealy International, Inc. reported 2017 net sales of $2,754.4 milliona, down 12.0% from $3,128.9 million in 2016, driven by the termination of its relationship with Mattress Firm, which was its largest customer in 2016 and represented 21.4% of 2016 sales.
Net income attributable to the company was $151.4 millionb ($2.77 diluted EPS) versus $190.6 million ($3.19) in 2016. Operating income fell to $288.4 million from $410.4 million, while adjusted EBITDA was $448.5 million compared with $521.6 million. The company said that excluding Mattress Firm, North America net sales increased $176.6 million, or 9.3%, in 2017.
Operating cash flow improved to $222.9 millionc from $165.5 million. Balance sheet and capital allocation: total debt was $1,762.5 million at year-end 2017, down from $1,901.0 million, and the company's ratio of funded debt less qualified cash to adjusted EBITDA was 3.91 times against a 5.00 times covenant limit. Management's target is 3.5 times, and it expects the ratio to be slightly above the target range in the first quarter of 2018.
The company repurchased 0.6 million shares for $40.1 milliond in 2017 and had $226.9 million remaining under its authorization, with repurchases possibly resuming in 2018. It pays no dividend.
Key risks and 2018 outlook: the filing highlights a pending Danish tax matter with SKAT, a major 2018 North America product launch that management says substantially drives 2018 performance, expected commodity cost inflation, foreign exchange headwinds, and pending securities class action and derivative litigation along with a dispute with Mattress Firm. The 2017 results also include a net income tax benefit of $23.8 million from the U.S. Tax Reform Act and charges tied to a Latin American subsidiary, which the company revised prior-period results to reflect.
02—Key points
Key Highlights
- Net sales fell 12.0% to $2,754.4 million in 2017, reflecting the termination of the Mattress Firm relationship; Mattress Firm was 21.4% of 2016 sales.
- Excluding Mattress Firm, North America net sales increased $176.6 million, or 9.3%, and International net sales rose 3.9% to $580.6 million.
- Operating income declined to $288.4 million from $410.4 million; adjusted operating income was $326.5 million, or 11.9% of net sales.
- Diluted EPS was $2.77 versus $3.19 in 2016; adjusted EPS was $3.20 versus $4.05.
- Total debt decreased to $1,762.5 million from $1,901.0 million; leverage was 3.91 times versus a 5.00 times covenant limit and a 3.5 times target.
- Operating cash flow rose to $222.9 million from $165.5 million, and the company repurchased $40.1 million of stock in 2017.
- A 2018 Tempur-Pedic product launch in North America is described as substantially determining 2018 financial performance, and the company expects commodity cost inflation that it plans to offset with price increases.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2017, Somnigroup International kept $0.06.
- Revenue$2.70B100.0%
- Cost of revenue−$1.58B58.5%
- Gross profit$1.12B41.5%
- Operating costs−$825.5M30.6%
- Operating income$295.5M10.9%
- Interest, other & tax−$144.1M5.3%
- Net income$151.4M5.6%
Where FY2017 revenue went
$2.70B- Cost of revenue: $1.58B, 58% of revenue
- Other operating costs: $803.8M, 30% of revenue
- Net income: $151.4M, 5.6% of revenue
- R&D: $21.7M, 0.8% of revenue
- Interest, other & tax: $144.1M, 5.3% of revenue
Kept 5.6% as net incomeNet income $151.4M · 5.6%R&D $21.7M · 0.8%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2017filed March 1, 2018Financial Statements
FY2017 against FY2016
| Line item | FY2017FY2016 | Change |
|---|---|---|
| Revenue | $2.70B$3.08B | −12.3% |
| Cost of Revenue | $1.58B$1.79B | −11.8% |
| Gross Profit | $1.12B$1.29B | −13.1% |
| R&D Expenses | $21.70M$26.70M | −18.7% |
| Operating Income | $295.50M$413.40M | −28.5% |
| Interest Expense | $87.30M$82.90M | +5.3% |
| Net Income | $151.40M$190.60M | −20.6% |
| EPS (Basic) | $2.80$3.23 | −13.3% |
| EPS (Diluted) | $2.77$3.19 | −13.2% |
| Shares Outstanding (Basic) | 54.00M59.00M | −8.5% |
| Shares Outstanding (Diluted) | 54.70M59.80M | −8.5% |
05—Questions
Frequently Asked Questions
Why did net sales decline in 2017?
Net sales fell 12.0% to $2,754.4 million because Tempur-Pedic and Sealy terminated the Mattress Firm relationship, effective April 3, 2017. Mattress Firm sales were $95.7 million before termination in 2017 versus $668.6 million in 2016. Excluding Mattress Firm, North America net sales rose 9.3%.
How did profitability change?
Operating income fell to $288.4 million from $410.4 million, and net income attributable to the company fell to $151.4 million from $190.6 million. The results include $25.9 million of net Mattress Firm termination charges, and the 2017 tax line includes a net $23.8 million benefit from the U.S. Tax Reform Act.
How much debt does the company carry and is it within covenants?
Total debt was $1,762.5 million at December 31, 2017. The ratio of consolidated funded debt less qualified cash to adjusted EBITDA was 3.91 times, within the 5.00 times covenant, and the company reported compliance with all financial covenants.
Will the company return capital to shareholders?
The company pays no dividend. It had $226.9 million remaining under its share repurchase authorization at year-end 2017, and it said it may resume repurchases sometime in 2018, subject to market conditions, with excess cash flow expected to go primarily to debt repayment.
What are the main risks flagged for investors?
The filing cites a pending Danish tax assessment from SKAT that could require significant payments, the success of the 2018 Tempur-Pedic launch, expected commodity cost increases, foreign exchange exposure, the effect of retailer consolidation and customer concentration, and securities class action, derivative, and Mattress Firm litigation for which the company cannot estimate a possible loss.
06—Continue